BCL2 and neoplasm: TNA ASO complementary to BcL-2 mRNA significantly reduced target mRNA and protein expression in cancer cells, as well as suppressed tumor cell growth and induced tumor cell death in carcinoma xenografts (D. Wang et al, 2019).